?one prior regimen of chemotherapy for Innovative breast most cancers and through the complete demo, former exposure to any FGFR inhibitor, significant surgical treatment or radiotherapy within just four months prior to 1st dose of review procedure and having potent inhibitors or inducers of CYP3A4 or CYP2D6. Any of the following cardiac requiremen